Novosti
Khirurgii
This journal is
indexed in Scopus



Year 2019 Vol. 27 No 1

CASE REPORTS

DOI: https://dx.doi.org/10.18484/2305-0047.2019.1.108   |  

R.V. KARPOVA, A.F. CHERNOUSOV, .V. KHOROBRYH, D.A. KAZAKOVA, YU.M. POLUEKTOV

LIVER REGENERATION AFTER INTRAHEPATIC INJECTION OF CRYOPRECIPITATE IN A PATIENT WITH CIRRHOSIS

I.M. Sechenov First Moscow State Medical University, Moscow,
The Russian Federation

Nowadays the mortality rate due to the liver cirrhosis has been steadily increasing. Conservative methods of treatment have a positive effect at an early stage of the disease in some patients. The amount of five-year survival rate is 62% in the compensation stage of cirrhosis whereas it decreases to 19% at the decompensation stage. At the present time, the most effective treatment of cirrhosis is liver transplantation because a five-year survival rate is 70-75%. However, this method is followed by the number of limitations. In this aspect, we give preference to minimally invasive techniques with the use of agents influencing an inflammation process and liver regeneration. This case report describes the clinical experience of seven-year observation of the patient with viral liver cirrhosis (HbsAg+, DNA HBV+, HDV+) in the decompensation stage (C-class by Child-Pugh) treated by the minimally invasive method: intrahepatic injection of cryoprecipitate. This contributed to the improvement of the general state and clinical and laboratory parameters for a long time. The cryoprecipitate is a highly concentrated solution of fibrinogen derived from donor plasma by cryoprecipitation, containing growth factors to decrease macrophage activity and cirrhosis progress. On admission, the patient had the unfavorable prognosis for the disease. However, the usage of cryoprecipitate showed significant improvement of the laboratory and hemodynamic tests. The effectiveness and availability of this method make it perspective for the treatment of the patients with liver cirrhosis in the stage of decompensation.

Keywords: liver cirrhosis, portal hypertension, surgical treatment, liver regeneration, minimally invasive surgery, cryoprecipitate, functional activity
p. 108-113 of the original issue
References
  1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray JL, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Medicine 2014 12:145. doi: 10.1186/s12916-014-0145-y
  2. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1
  3. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 2012 Jan;32(1):79-84. doi: 10.1111/j.1478-3231.2011.02517.x
  4. Tovikkai C, Charman SC, Praseedom RK, Gimson AE, van der Meulen J. Time-varying impact of comorbidities on mortality after liver transplantation: a national cohort study using linked clinical and administrative data. BMJ Open. 2015 May 14;5(5):e006971. doi: 10.1136/bmjopen-2014-006971
  5. Forbes SJ, Newsome PN. Liver regeneration - mechanisms and models to clinical application. Nat Rev Gastroenterol Hepatol. 2016 Aug;13(8):473-85. doi: 10.1038/nrgastro.2016.97
  6. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology. 2006 Feb;43(2 Suppl 1):S45-53. doi: 10.1002/hep.20969
  7. Chernousov AF, Khorobrykh TV, Karpova RV, Zenkova KI. Effect of cryoprecipitate on liver regeneration in cirrhosis. Novosti Khirurgii. 2017;25(4):350-58. doi: 10.18484/2305-0047.2017.4.350 (in Russ.)
Address for correspondence:
119435, The Russian Federation,
Moscow, B. Pirogovskaya Str., 6-1,
I.M. Sechenov First Moscow
State Medical University,
Department of Faculty Surgery 1.
Tel.: +7 916 407-75-70,
e-mail: yuripoul@gmail.com,
Yuri M. Poluektov
Information about the authors:
Karpova Radmila V., MD, Professor of the Department of Faculty Surgery 1, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
https://orcid.org/0000-0003-0608-9846
Chernousov Alexander F., Academician of RAS, MD, Professor, Head of the Department of Faculty Surgery 1, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
https://orcid.org/0000-0001-8792-1459
Khorobryh Tatiana V., MD, Professor of the Department of Faculty Surgery 1, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
https://orcid.org/0000-0001-5769-5091
Kazakova Daria A., 5-Year Student of the Faculty Medicine of Future, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
https://orcid.org/0000-0001-7344-6124
Poluektov Yuri M., 5-Year Student of the Faculty Medicine of Future, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
https://orcid.org/0000-0002-9710-7490
Contacts | ©Vitebsk State Medical University, 2007